Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $195.90.
Several analysts have recently weighed in on JAZZ shares. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $200.00 to $191.00 and set an “outperform” rating for the company in a report on Thursday, November 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $225.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, November 29th. Truist Financial reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, December 4th. Barclays dropped their price target on Jazz Pharmaceuticals from $240.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, January 29th. Finally, Robert W. Baird began coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price target on the stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of JAZZ. BlackRock Inc. increased its position in Jazz Pharmaceuticals by 3.3% during the 2nd quarter. BlackRock Inc. now owns 6,879,285 shares of the specialty pharmaceutical company’s stock worth $852,825,000 after purchasing an additional 222,801 shares during the period. Vanguard Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after buying an additional 29,960 shares during the last quarter. Wellington Management Group LLP increased its holdings in Jazz Pharmaceuticals by 7.5% in the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after purchasing an additional 184,124 shares in the last quarter. State Street Corp grew its stake in shares of Jazz Pharmaceuticals by 1.8% during the second quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock valued at $294,106,000 after acquiring an additional 42,703 shares in the last quarter. Finally, LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 2.4% during the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after purchasing an additional 55,630 shares during the last quarter. 88.15% of the stock is currently owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Stock Performance
Jazz Pharmaceuticals stock opened at $124.24 on Tuesday. Jazz Pharmaceuticals has a one year low of $111.25 and a one year high of $152.90. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.67 and a current ratio of 2.06. The firm has a market capitalization of $7.82 billion, a PE ratio of 141.18, a price-to-earnings-growth ratio of 0.94 and a beta of 0.62. The stock’s 50 day moving average price is $122.07 and its 200 day moving average price is $127.82.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
- Five stocks we like better than Jazz Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- 3 attractive stocks that insiders are buying
- Why Are Stock Sectors Important to Successful Investing?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Are Low Beta Stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.